Valeant Pharmaceuticals International Inc. (NYSE: VRX) has raised its bid for bankrupt cancer drug company Dendreon to $400 million from $296 million. 

The deadline for other bids remains Feb. 10. If other bids come in, an auction will be held Feb. 12.

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.